Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

ecrease reflects operating expenditures of $22.8 million in 2007 offset by $15.8 million in cash received under the Company's collaborative and contract manufacturing agreements. The decrease was also offset by the favorable effect of exchange rate fluctuations on cash and cash equivalents of $1.7 million and short-term investments of $1.9 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

For 2008, Oncothyreon expects expenses to increase over 2007 as a result of increased manufacturing and process development activities for Stimuvax(R) and more advanced clinical development activity for the Company's small molecule drugs. The Company expects these expenses to be partially offset by increased revenue related to the purchase of Stimuvax clinical supplies by Merck KGaA. As a result, Oncothyreon anticipates that operating cash requirements for 2008 will be between $17 million and $19 million. The Company estimates that it currently has sufficient cash resources to last into the second quarter of 2009.

Business Update

Key achievements for Oncothyreon in 2007 included:

- Initiating a Phase 2 trial of PX-12 in patients with advanced

pancreatic cancer.

- Initiating the START trial, a Phase 3 trial of Stimuvax in patients

with Stage III non-small cell lung cancer, in partnership with

Merck KGaA.

- Successfully manufacturing Stimuvax vaccine and placebo for the START

trial.

- Filing an IND and initiating a Phase 1 trial of PX-478 in patients

with advanced solid tumors or lymphomas.

- Signing amended and restated collaboration and supply agreements with

Merck KGaA for Stimuvax, providing for new, near-term milestones, the

first of which was received
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... 2014 Continuing its award-winning streak, Nerium ... prestigious MarCom Awards for outstanding creative achievement by its ... MarCom Award, the organization’s top honor, in the Branding ... held in April of this year. The event showcased ... Additionally, Nerium was awarded a Gold MarCom Award in ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 25, 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens, today announced that ... Jaffray  26 th Annual Healthcare Conference on December 2, ... The New York Palace in New York, NY ... concerning the Company, its operations, strategies and prospects may be ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... Faster delivery, efficient supply chain, and reduced cost for ... ... of America,(SCOA) has reached an agreement with Chiral Quest, Inc., ... for the,distribution and sale of chiral products to the pharmaceutical ...
... ON, April 14 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... a strategic,restructuring plan to significantly reduce its cash ... the Board and management believe are most,likely to ... on the development of its VP series of ...
... Informatics, the,technology subsidiary of PAREXEL International Corporation ... of its clinical site management and,monitoring software, ... Clinical,monitors can now securely upload site visit ... laptop computers with them. The MySites monitoring,solution ...
Cached Biology Technology:Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2Vasogen Announces Implementation of Strategic Restructuring Plan 2Vasogen Announces Implementation of Strategic Restructuring Plan 3Vasogen Announces Implementation of Strategic Restructuring Plan 4Vasogen Announces Implementation of Strategic Restructuring Plan 5Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability 2Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability 3Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability 4
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... This release is available in French . ... can stunt growth and foster weight gain during puberty, ... Journal of Clinical Endocrinology & Metabolism . Even in ... Centre (MUHC) and the University of Southern California conducted ...
... Fluorescent molecules i.e. substances which can be stimulated ... biological research and medical diagnosis. Fluorescence can be used ... genes, to locate proteins in cells and tissues, to ... migration of cells. Of particular importance is the combination ...
... chemical additives and refined sweeteners in commercial salad dressings, ... capitalize on the positive health effects of honey, we ... Engeseth, a U of I associate professor of food ... the quality of the salad dressings for up to ...
Cached Biology News:Lack of vitamin D causes weight gain and stunts growth in girls 2Novel technique for fluorescence tomography of tumors in living animals 2Honey adds health benefits, is natural preservative and sweetener in salad dressings 2
Mouse BLC/BCA 1 - 10kDa...
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: